Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK inhibitor.
July 29, 2026 10:46 AM EDT
Deals
Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
Kyle LaHucik
Biotech Correspondent
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public…
Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for…
Apogee details its $10.9B AbbVie buyout, the UK launches a drug-pricing pilot, and Brii shares Phase 2b HBV vaccine data.
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded…
